As of Apr 17
| +0.14 / +3.70%|
The 1 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 5.50, with a high estimate of 5.50 and a low estimate of 5.50. The median estimate represents a +40.31% increase from the last price of 3.92.
The current consensus among 1 polled investment analysts is to Buy stock in Rosetta Genomics Ltd. This rating has held steady since April, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.